Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

OPDIVO QVANTIG: unresectable metastatic Colorectal Cancer with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy.

Broader topic: Childhood Colorectal Cancer

Source population
pediatric
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
  1. gene
    MSI-H
    alteration
    stated without a specific alteration
    status
    present
  2. gene
    DMMR
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    following treatment with intravenous nivolumab and ipilimumab combination therapy
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for OPDIVO QVANTIG (product label). Only dimensions stated in that wording are part of this definition.
source wording
1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy.

Study evidence for this setting

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice